Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence.
This post hoc analysis compared the safety of atomoxetine treatment of ADHD in adults with or without comorbid alcohol abuse/dependence. Study completion rates in patients receiving atomoxetine were comparable between heavy drinkers (60.9%) and patients with no alcohol-use disorder (71.0%) but lower in nonheavy drinkers (35.7%); however, there was no significant difference in discontinuation rates due to adverse events or lack of efficacy among these groups. Alcohol-use disorder patients, especially heavy drinkers, generally experienced the greatest frequency of treatment-emergent adverse events in both the atomoxetine and placebo groups. Vital signs and measures of hepatic function were not significantly different among the 3 drinking status groups taking atomoxetine.
Adler
Lenard
L
Department of Psychiatry and Child and Adolescent Psychiatry, New York University Langone School of Medicine, 530 First Avenue, #7D, New York NY 10016, USA. lenard.adler@med.nyu.edu
Wilens
Timothy
T
Zhang
Shuyu
S
Durell
Todd
T
Walker
Daniel
D
Schuh
Leslie
L
Jin
Ling
L
Feldman
Peter
P
Trzepacz
Paula
P
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000328:Adult; D000437:Alcoholism / Q000150:complications / Q000188:drug therapy*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy*; D017831:Diagnosis, Dual (Psychiatry); D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D011437:Propylamines / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D055986:Vital Signs
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride